Table 3 Copy-neutral loss of... | American Society of Hematology

Table 3

Copy-neutral loss of heterozygosity

Chromosome	Probe ID	Start	Stop	Length, mb	Cytoband	IGHV mutational status		FISH					TP53 mutation
Chromosome	Probe ID	Start	Stop	Length, mb	Cytoband	Mutated	Unmutated	Normal	Del(13q)	+12	Del(11q)	Del(17p)	TP53 mutation
1	CLL037	554 484	49 046 634	48 492 150	pter-p33		X		X
3	CLL032	41 866	199 340 830	199 298 964	pter-qter		X			X
11	CLL032	188 260	2 707 910	2 519 650	p15.5		X			X
	CLL175up	65 369 924	134 449 982	69 080 058	q13.1-qter		X				X		NA
	CLL243up	71 431 230	134 449 982	63 018 752	q13.4-qter		X		X		X
12	CLL058	89 090 531	132 287 718	43 197 187	q21.33-qter	X			X				NA
13	CLL041	26 496 372	114 125 098	87 628 726	q12.13-qter		X		X _bidel
	CLL070	18 876 771	114 125 098	95 248 327	q12.11-qter		X		X _bidel
	CLL110	19 273 074	114 125 098	94 852 024	q12.11-qter	X			X _bidel
	CLL211up	45 637 626	114 125 098	68 487 472	q14.12-qter	X			X _bidel
	CLL213up	20 194 267	114 125 098	93 930 831	q12.11-qter	X			X _bidel
	CLL234up	18 833 721	114 125 098	95 291 377	q12.11-qter		X		X _bidel
	CLL235up	21 684 026	114 125 098	92 441 072	q12.11-qter		X		X _bidel
	CLL288up	17 963 628	114 125 098	96 161 470	q11-qter		X		X _bidel
	CLL315up	44 533 321	114 125 098	69 591 777	q14.12-qter		X		X _bidel
	CLL353up	26 698 826	114 125 098	87 426 272	q12.13-qter	X			X _bidel	X
17	CLL067	6689	13 997 853	13 991 164	pter-p12	X			X				X
	CLL185up	6689	17 985 823	17 979 134	pter-p11.2		X		X				X
	CLL244up	6689	20 649 281	20 642 592	pter-p11.2		X		X				X
22	CLL094	15 909 583	49 565 872	33 656 289	q11.1-qter		X	X

Chromosome	Probe ID	Start	Stop	Length, mb	Cytoband	IGHV mutational status		FISH					TP53 mutation
Chromosome	Probe ID	Start	Stop	Length, mb	Cytoband	Mutated	Unmutated	Normal	Del(13q)	+12	Del(11q)	Del(17p)	TP53 mutation
1	CLL037	554 484	49 046 634	48 492 150	pter-p33		X		X
3	CLL032	41 866	199 340 830	199 298 964	pter-qter		X			X
11	CLL032	188 260	2 707 910	2 519 650	p15.5		X			X
	CLL175up	65 369 924	134 449 982	69 080 058	q13.1-qter		X				X		NA
	CLL243up	71 431 230	134 449 982	63 018 752	q13.4-qter		X		X		X
12	CLL058	89 090 531	132 287 718	43 197 187	q21.33-qter	X			X				NA
13	CLL041	26 496 372	114 125 098	87 628 726	q12.13-qter		X		X _bidel
	CLL070	18 876 771	114 125 098	95 248 327	q12.11-qter		X		X _bidel
	CLL110	19 273 074	114 125 098	94 852 024	q12.11-qter	X			X _bidel
	CLL211up	45 637 626	114 125 098	68 487 472	q14.12-qter	X			X _bidel
	CLL213up	20 194 267	114 125 098	93 930 831	q12.11-qter	X			X _bidel
	CLL234up	18 833 721	114 125 098	95 291 377	q12.11-qter		X		X _bidel
	CLL235up	21 684 026	114 125 098	92 441 072	q12.11-qter		X		X _bidel
	CLL288up	17 963 628	114 125 098	96 161 470	q11-qter		X		X _bidel
	CLL315up	44 533 321	114 125 098	69 591 777	q14.12-qter		X		X _bidel
	CLL353up	26 698 826	114 125 098	87 426 272	q12.13-qter	X			X _bidel	X
17	CLL067	6689	13 997 853	13 991 164	pter-p12	X			X				X
	CLL185up	6689	17 985 823	17 979 134	pter-p11.2		X		X				X
	CLL244up	6689	20 649 281	20 642 592	pter-p11.2		X		X				X
22	CLL094	15 909 583	49 565 872	33 656 289	q11.1-qter		X	X

To be considered as a true tumor-specific CN-LOH, defects had to have homozygous SNPs in at least 20 consecutive markers containing less than 10% intervening or conflicting calls. In unpaired (up) analyzed patients, regions of CN-LOH had to be larger than 10 Mb and had to coincide with a proven tumor-specific CN-LOH or CNA.

NA indicates not applicable.

View Large

This Feature Is Available To Subscribers Only